Search
Isoeugenol
go.drugbank.com/drugs/DB14188ApprovedIt is also a significant dermatologic sensitizer and allergen, and as a result has been restricted to 200 p.p.m. since 1998 according to guidelines issued by the fragrance industry [A34278]. … Allergic reactivity to Isoeugenol may be identified with a patch test.
Ropinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalIn 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. … It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.
Tramadol
go.drugbank.com/drugs/DB00193ApprovedInvestigationalTramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the … [A4269,A183842] Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Noax uno 100 mg Retardtabletten, TRAMADOL SANDOZ UNO 150MGMilnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalFurthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia [F3925], although other regional regulatory authorities like the EMA, among others, have not … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment
Categories: Analgesics, Non-Narcotic, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProtriptyline
go.drugbank.com/drugs/DB00344ApprovedIn non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. … The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission.
Categories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine, N-methyl-5H-dibenzo[a,d]cycloheptene-5-propanamineNecitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnIt functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression … Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist.
Reslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalReslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. … Studies demonstrated that reslizumab was not effective in various asthma outcomes in patients without eosinophilia [A31577]. Reslizumab was developed by Teva Pharmaceuticals.
Camizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] Patients are selected for treatment on the basis of an *ESR1* mutation detected by circulating tumor DNA testing during first-line endocrine therapy, before radiographic disease progression … [L64094,L64107] It binds the ligand binding domain of ERα, antagonizing ERα encoded by both wild-type and mutated *ESR1* and inducing proteasome-dependent degradation of the receptor without agonizing
Synonyms: 3-pyridinamine, n-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamineTroglitazone
go.drugbank.com/drugs/DB00197ApprovedWithdrawnTroglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Aztreonam
go.drugbank.com/drugs/DB00355ApprovedInvestigationalIt is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.